Download PDF
Semin Thromb Hemost 2017; 43(06): 591-598
DOI: 10.1055/s-0037-1602663
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hematocrit and Stroke: A Forgotten and Neglected Link?

Konstantinos Stavropoulos
1   Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Konstantinos P. Imprialos
1   Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Sofia Bouloukou
1   Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Chrysoula Boutari
1   Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Michael Doumas
2   VAMC and George Washington University, Washington, District of Columbia
› Author Affiliations
Further Information

Publication History

Publication Date:
13 June 2017 (online)

    Permissions and Reprints

Abstract

Stroke is considered among the most common causes of mortality and disability, leading to dramatic socioeconomic consequences. From a pathophysiologic perspective, enhanced blood viscosity due to increased hematocrit might be associated with stroke through impaired cerebral blood perfusion. This association has remained rather neglected during previous decades, but newly emerged as an epicenter of scientific interest due to the unexpected elevation of stroke rates with sodium-glucose cotransporter-2 inhibitors, a new class of hypoglycemic drugs with otherwise dramatic cardiovascular benefits. The purpose of this article is to review available data on the relation between stroke and hematocrit values. Data from large observational studies point toward an increased risk for stroke in individuals with elevated hematocrit. Data also suggest that the coexistence of increased hematocrit values and hypertension significantly enhance the risk of cerebrovascular events compared with each condition alone. Additionally, high hematocrit values seem related to worse survival outcomes in post-stroke patients. Collectively, the association between hematocrit and stroke seems to be strong and independent in high hematocrit values (>0.50) in both previously healthy individuals and post-stroke patients, but remains less clarified in patients with normal hematocrit values.

Keywords

blood viscosity - hyperviscosity - cerebrovascular disease - hematocrit - stroke
 

  • References

  • 1 Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371 (9624): 1612-1623
    CrossrefPubMedGoogle Scholar
  • 2 Krishnamurthi RV, Feigin VL, Forouzanfar MH. , et al; Global Burden of Diseases, Injuries, Risk Factors Study 2010 (GBD 2010); GBD Stroke Experts Group. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 2013; 1 (05) e259-e281
    CrossrefPubMedGoogle Scholar
  • 3 Mozaffarian D, Benjamin EJ, Go AS. , et al; Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016; 133 (04) e38-e360
    CrossrefPubMedGoogle Scholar
  • 4 Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MS. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006; 66 (05) 641-646
    CrossrefPubMedGoogle Scholar
  • 5 Kernan WN, Ovbiagele B, Black HR. , et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (07) 2160-2236
    CrossrefPubMedGoogle Scholar
  • 6 Thom T, Haase N, Rosamond W. , et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113 (06) e85-e151
    CrossrefPubMedGoogle Scholar
  • 7 O'Donnell MJ, Xavier D, Liu L. , et al; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376 (9735): 112-123
    CrossrefPubMedGoogle Scholar
  • 8 Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997; 96 (01) 168-173
    CrossrefPubMedGoogle Scholar
  • 9 Jeong SK, Cho YI, Duey M, Rosenson RS. Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment?. Cardiovasc Drugs Ther 2010; 24 (02) 151-160
    CrossrefPubMedGoogle Scholar
  • 10 Brun JF, Bouchahda C, Chaze D, Benhaddad AA, Micallef JP, Mercier J. The paradox of hematocrit in exercise physiology: which is the “normal” range from an hemorheologist's viewpoint?. Clin Hemorheol Microcirc 2000; 22 (04) 287-303
    PubMedGoogle Scholar
  • 11 Coull BM, Beamer N, de Garmo P. , et al. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke 1991; 22 (02) 162-168
    CrossrefPubMedGoogle Scholar
  • 12 Imprialos KP, Boutari C, Stavropoulos K, Doumas M, Karagiannis AI. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. J Neurol Neurosurg Psychiatry 2017; 88 (03) 249-253
    CrossrefPubMedGoogle Scholar
  • 13 Zinman B, Wanner C, Lachin JM. , et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373 (22) 2117-2128
    CrossrefPubMedGoogle Scholar
  • 14 Wu JH, Foote C, Blomster J. , et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4 (05) 411-419
    CrossrefPubMedGoogle Scholar
  • 15 Lowe GD, Forbes CD. Blood rheology and thrombosis. Clin Haematol 1981; 10 (02) 343-367
    PubMedGoogle Scholar
  • 16 Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Nerem RM. The pathogenesis of atherosclerosis: an overview. Clin Cardiol 1991; 14 (02) (Suppl. 01) I1-I16
    PubMedGoogle Scholar
  • 17 Liepsch D, Moravec S. Pulsatile flow of non-Newtonian fluid in distensible models of human arteries. Biorheology 1984; 21 (04) 571-586
    CrossrefPubMedGoogle Scholar
  • 18 Koenig W, Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992; 94 (2-3): 93-107
    CrossrefPubMedGoogle Scholar
  • 19 Dormandy JA. Medical and engineering problems of blood viscosity. Biomed Eng 1974; 9 (07) 284-289
    PubMedGoogle Scholar
  • 20 Lowe GD. Blood rheology in arterial disease. Clin Sci (Lond) 1986; 71 (02) 137-146
    CrossrefPubMedGoogle Scholar
  • 21 Turitto VT, Weiss HJ. Platelet and red cell involvement in mural thrombogenesis. Ann N Y Acad Sci 1983; 416: 363-376
    CrossrefPubMedGoogle Scholar
  • 22 Cecchi E, Marcucci R, Poli D. , et al. Hyperviscosity as a possible risk factor for cerebral ischemic complications in atrial fibrillation patients. Am J Cardiol 2006; 97 (12) 1745-1748
    CrossrefPubMedGoogle Scholar
  • 23 Fung YC. Biomechanics: Mechanical Properties of Living Tissues. New York: Springer-Verlag; 1981: 108-113
    Google Scholar
  • 24 Gachtgens P, Pries AR, Ley K. Structural hemodynamic and rheological characteristics of blood flow in the circulation. In: Chein S, Dormandy J, Ernst E, Matrai A. , eds. Clinical Hemorheology: Applications in Cardiovascular and Haematological Disease, Diabetes, Surgery, and Gynecology. Boston, MA: Martinus Nijhoff; 1987: 97-124
    Google Scholar
  • 25 Leonhardt H, Arntz HR, Klemens UH. Studies of plasma viscosity in primary hyperlipoproteinaemia. Atherosclerosis 1977; 28 (01) 29-40
    CrossrefPubMedGoogle Scholar
  • 26 Seplowitz AH, Chien S, Smith FR. Effects of lipoproteins on plasma viscosity. Atherosclerosis 1981; 38 (1-2): 89-95
    CrossrefPubMedGoogle Scholar
  • 27 Rosenson RS, Baker AL, Chow MJ, Hay RV. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology 1990; 98 (5, Pt 1): 1351-1357
    CrossrefPubMedGoogle Scholar
  • 28 Kwaan HC, Bongu A. The hyperviscosity syndromes. Semin Thromb Hemost 1999; 25 (02) 199-208
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003; 29 (05) 451-458
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Li RY, Cao ZG, Li Y, Wang RT. Increased whole blood viscosity is associated with silent cerebral infarction. Clin Hemorheol Microcirc 2015; 59 (04) 301-307
    PubMedGoogle Scholar
  • 31 Ernst E, Resch KL, Matrai A, Buhl M, Schlosser P, Paulsen HF. Impaired blood rheology: a risk factor after stroke?. J Intern Med 1991; 229 (05) 457-462
    CrossrefPubMedGoogle Scholar
  • 32 Levy BI, Schiffrin EL, Mourad JJ. , et al. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation 2008; 118 (09) 968-976
    CrossrefPubMedGoogle Scholar
  • 33 Fukuda S, Yasu T, Kobayashi N, Ikeda N, Schmid-Schönbein GW. Contribution of fluid shear response in leukocytes to hemodynamic resistance in the spontaneously hypertensive rat. Circ Res 2004; 95 (01) 100-108
    CrossrefPubMedGoogle Scholar
  • 34 Tamariz LJ, Young JH, Pankow JS. , et al. Blood viscosity and hematocrit as risk factors for type 2 diabetes mellitus: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol 2008; 168 (10) 1153-1160
    CrossrefPubMedGoogle Scholar
  • 35 Frangos SG, Gahtan V, Sumpio B. Localization of atherosclerosis: role of hemodynamics. Arch Surg 1999; 134 (10) 1142-1149
    CrossrefPubMedGoogle Scholar
  • 36 Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999; 282 (21) 2035-2042
    CrossrefPubMedGoogle Scholar
  • 37 Lee AJ, Mowbray PI, Lowe GD, Rumley A, Fowkes FG, Allan PL. Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation 1998; 97 (15) 1467-1473
    CrossrefPubMedGoogle Scholar
  • 38 Ernst E, Weihmayr T, Schmid M, Baumann M, Matrai A. Cardiovascular risk factors and hemorheology. Physical fitness, stress and obesity. Atherosclerosis 1986; 59 (03) 263-269
    CrossrefPubMedGoogle Scholar
  • 39 Lowe GD, Drummond MM, Forbes CD, Barbenel JC. The effects of age and cigarette-smoking on blood and plasma viscosity in men. Scott Med J 1980; 25 (01) 13-17
    CrossrefPubMedGoogle Scholar
  • 40 Coppola L, Caserta F, Guastafierro S. , et al; De Lucia D. Blood viscosity and aging. Arch Gerontol Geriatr 2000; 31 (01) 35-42
    CrossrefPubMedGoogle Scholar
  • 41 Devereux RB, Case DB, Alderman MH, Pickering TG, Chien S, Laragh JH. Possible role of increased blood viscosity in the hemodynamics of systemic hypertension. Am J Cardiol 2000; 85 (10) 1265-1268
    CrossrefPubMedGoogle Scholar
  • 42 Fowkes FG, Lowe GD, Rumley A, Lennie SE, Smith FB, Donnan PT. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J 1993; 14 (05) 597-601
    CrossrefPubMedGoogle Scholar
  • 43 Smith WC, Lowe GD, Lee AJ, Tunstall-Pedoe H. Rheological determinants of blood pressure in a Scottish adult population. J Hypertens 1992; 10 (05) 467-472
    CrossrefPubMedGoogle Scholar
  • 44 Levenson J, Simon AC, Cambien FA, Beretti C. Cigarette smoking and hypertension. Factors independently associated with blood hyperviscosity and arterial rigidity. Arteriosclerosis 1987; 7 (06) 572-577
    CrossrefPubMedGoogle Scholar
  • 45 Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration. Am J Med 1981; 70 (06) 1195-1202
    CrossrefPubMedGoogle Scholar
  • 46 Sloop GD, Garber DW. The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humans. Clin Sci (Lond) 1997; 92 (05) 473-479
    CrossrefPubMedGoogle Scholar
  • 47 Rosenson RS, McCormick A, Uretz EF. Distribution of blood viscosity values and biochemical correlates in healthy adults. Clin Chem 1996; 42 (8, Pt 1): 1189-1195
    PubMedGoogle Scholar
  • 48 de Simone G, Devereux RB, Chien S, Alderman MH, Atlas SA, Laragh JH. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation 1990; 81 (01) 107-117
    CrossrefPubMedGoogle Scholar
  • 49 Rosenson RS, Shott S, Tangney CC. Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Atherosclerosis 2002; 161 (02) 433-439
    CrossrefPubMedGoogle Scholar
  • 50 Stamos TD, Rosenson RS. Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis 1999; 146 (01) 161-165
    CrossrefPubMedGoogle Scholar
  • 51 Høieggen A, Fossum E, Moan A, Enger E, Kjeldsen SE. Whole-blood viscosity and the insulin-resistance syndrome. J Hypertens 1998; 16 (02) 203-210
    CrossrefPubMedGoogle Scholar
  • 52 Lowe GD. Blood viscosity, lipoproteins, and cardiovascular risk. Circulation 1992; 85 (06) 2329-2331
    CrossrefPubMedGoogle Scholar
  • 53 Jax TW, Peters AJ, Plehn G, Schoebel FC. Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patients. Cardiovasc Diabetol 2009; 8: 48
    CrossrefPubMedGoogle Scholar
  • 54 Cho YI, Mooney MP, Cho DJ. Hemorheological disorders in diabetes mellitus. J Diabetes Sci Technol 2008; 2 (06) 1130-1138
    CrossrefPubMedGoogle Scholar
  • 55 Carroll S, Cooke CB, Butterly RJ. Plasma viscosity, fibrinogen and the metabolic syndrome: effect of obesity and cardiorespiratory fitness. Blood Coagul Fibrinolysis 2000; 11 (01) 71-78
    CrossrefPubMedGoogle Scholar
  • 56 Ernst E, Koenig W, Matrai A, Filipiak B, Stieber J. Blood rheology in healthy cigarette smokers. Results from the MONICA project, Augsburg. Arteriosclerosis 1988; 8 (04) 385-388
    CrossrefPubMedGoogle Scholar
  • 57 Ernst E. Haemorheological consequences of chronic cigarette smoking. J Cardiovasc Risk 1995; 2 (05) 435-439
    CrossrefPubMedGoogle Scholar
  • 58 Purves WK, Sadava D, Orians GH, Heller H. Life: The Science of Biology, 7th ed. Sunderland, MA: Sinauer Associates; 2004
    Google Scholar
  • 59 Grotta J, Ackerman R, Correia J, Fallick G, Chang J. Whole blood viscosity parameters and cerebral blood flow. Stroke 1982; 13 (03) 296-301
    CrossrefPubMedGoogle Scholar
  • 60 Thomas DJ, Marshall J, Russell RW. , et al. Effect of haematocrit on cerebral blood-flow in man. Lancet 1977; 2 (8045): 941-943
    PubMedGoogle Scholar
  • 61 Häggendal E, Nilsson NJ, Norbäck B. Rheological aspects of cerebral blood flow and oxygen consumption. An experimental study in dogs. Acta Chir Scand Suppl 1966; 364: 1-49
    PubMedGoogle Scholar
  • 62 Willison JR, Thomas DJ, du Boulay GH. , et al. Effect of high haematocrit on alertness. Lancet 1980; 1 (8173): 846-848
    PubMedGoogle Scholar
  • 63 Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera. Acta Med Scand 1962; 172: 513-523
    PubMedGoogle Scholar
  • 64 Millikan CH, Siekert RG, Whisnant JP. Intermittent carotid and vertebral-basilar insufficiency associated with polycythemia. Neurology 1960; 10: 188-196
    CrossrefPubMedGoogle Scholar
  • 65 Stone HO, Thompson Jr HK, Schmidt-Nielsen K. Influence of erythrocytes on blood viscosity. Am J Physiol 1968; 214 (04) 913-918
    PubMedGoogle Scholar
  • 66 Drüeke TB, Locatelli F, Clyne N. , et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355 (20) 2071-2084
    CrossrefPubMedGoogle Scholar
  • 67 Singh AK, Szczech L, Tang KL. , et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355 (20) 2085-2098
    CrossrefPubMedGoogle Scholar
  • 68 Besarab A, Bolton WK, Browne JK. , et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339 (09) 584-590
    CrossrefPubMedGoogle Scholar
  • 69 Pfeffer MA, Burdmann EA, Chen CY. , et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361 (21) 2019-2032
    CrossrefPubMedGoogle Scholar
  • 70 Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost 2010; 36 (05) 537-549
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents--time for a reevaluation. N Engl J Med 2010; 362 (03) 189-192
    CrossrefPubMedGoogle Scholar
  • 72 Gordon T, Sorlie P, Kannel WB. Coronary Heart Disease, Atherothrombotic Brain Infraction, Intermittent Claudication—A Multivariable Analysis of Some Factors Related to Their Incidence: Framingham Study, 16-Year Follow-up. Washington, DC: US Government Printing Office; 1971
    Google Scholar
  • 73 Kannel WB, Gordon T, Wolf PA, McNamara P. Hemoglobin and the risk of cerebral infarction: the Framingham Study. Stroke 1972; 3 (04) 409-420
    CrossrefPubMedGoogle Scholar
  • 74 Tohgi H, Yamanouchi H, Murakami M, Kameyama M. Importance of the hematocrit as a risk factor in cerebral infarction. Stroke 1978; 9 (04) 369-374
    CrossrefPubMedGoogle Scholar
  • 75 Kiyohara Y, Ueda K, Hasuo Y. , et al. Hematocrit as a risk factor of cerebral infarction: long-term prospective population survey in a Japanese rural community. Stroke 1986; 17 (04) 687-692
    CrossrefPubMedGoogle Scholar
  • 76 Lowe GD, Jaap AJ, Forbes CD. Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet 1983; 1 (8328): 784-786
    PubMedGoogle Scholar
  • 77 Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease--the Framingham study: a 34-year follow-up. Am Heart J 1994; 127 (03) 674-682
    CrossrefPubMedGoogle Scholar
  • 78 Wannamethee G, Perry IJ, Shaper AG. Haematocrit, hypertension and risk of stroke. J Intern Med 1994; 235 (02) 163-168
    CrossrefPubMedGoogle Scholar
  • 79 Sacco S, Marini C, Olivieri L, Pistoia F, Carolei A. Contribution of hematocrit to early mortality after ischemic stroke. Eur Neurol 2007; 58 (04) 233-238
    CrossrefPubMedGoogle Scholar
  • 80 Gotoh S, Hata J, Ninomiya T. , et al. Hematocrit and the risk of cardiovascular disease in a Japanese community: The Hisayama Study. Atherosclerosis 2015; 242 (01) 199-204
    CrossrefPubMedGoogle Scholar
  • 81 Turcato G, Cappellari M, Follador L. , et al. Red blood cell distribution width is an independent predictor of outcome in patients undergoing thrombolysis for ischemic stroke. Semin Thromb Hemost 2017; 43 (01) 30-35
    Article in Thieme ConnectPubMedGoogle Scholar